Type:10 Tablets
Generic Name:Almotriptan
Manufacturer:NIPRO JMI Pharma Limited
Price:৳250.80
Oral Acute migraine attacks Adult: Initially, 6.25-12.5 mg. May repeat 2 hr later if needed. Max: 2 doses/24 hr. Hepatic Impairment Initially, 6.25 mg as a single dose. Max: 12.5 mg/24 hr. Avoid in severe impairment.
Increased risk of serotonin syndrome when used with SSRIs or serotonin norepinephrine reuptake inhibitors. Increased plasma concentrations when used with verapamil, ketoconazole or other potent CYP450 inhibitors. Potentially Fatal: Severe vasospastic reactions may occur when given within 24 hr of treatment with another 5-HT1 agonist, or an ergotamine-containing or ergot-like medication. Avoid usage with or within 2 wk of stopping treatment with a MAOI.
Hypersensitivity to sulfonamides. Hepatic or moderate-severe renal impairment. Caution when used in patients with a history of seizures. May significantly increase BP. May cause drowsiness. Children <18 yr. Pregnancy, lactation. Lactation: excretion in milk unknown; use with caution
Almotriptan is a selective serotonin agonist which acts mainly on the 5-HT1 receptors and produces cranial vasodilation. It is used for the acute treatment of migraine.
Oral Child: Migraine Indicated for acute treatment of migraine headache pain in adolescents with a history of migraine attacks with or without aura usually lasting >4 hr (when untreated) <12 years: Safety and efficacy not established >12 years: 6.25-12.5 mg PO at onset of headache; may repeat once after 2 hr Not to exceed 25 mg/day
May be taken with or without food.
Migraine headache, Acute migraine attacks
Renal Impairment Initially, 6.25 mg as a single dose. Max: 12.5 mg/24 hr.
1-10% Somnolence (1-5%),Dizziness (3-4%),Nausea (1-3%),Vomiting (2%),Dry mouth (1-2%),Headache (1-2%),Nausea (1-2%),Paresthesia (1-2%),Paresthesia (1%),Somnolence (>1%) <1% Infrequent (0.01-0.001%) Anxiety, asthenia, chills, CNS stimulation, fatigue, hypesthesia, tremor, Pruitus, rash, Diaphoresis, dysmenorrhea, hyperglycemia, increased thirst, Abdominal cramp, gastroenteritis Back pain, myalgia, neck pain, rigid neck, Increased CPK, Bronchitis, chest pain, dyspnea, pharyngitis, rhinitis, sinusitis, Conjunctivitis, tinnitis, vertigo Potentially Fatal: Serious cardiac events.
Underlying CV disease e.g. ischaemic heart disease or coronary artery vasospasm. Uncontrolled hypertension. Severe hepatic or renal impairment. Prophylaxis of migraine, hemiplegic or basilar migraine; cluster headache. Use within 24 hr of another 5-HT1 agonist; use within 24 hr of ergotamine derivative; concurrent use or within 2 wk of discontinuing an MAOI.
